USFDA approves Biocon’s Biosimilar for autoimmune diseases
USFDA approves Biocon’s biosimilar for autoimmune diseases, YESINTEK, revolutionising treatments for inflammatory conditions like Crohn’s and psoriasis. This milestone underscores Biocon’s commitment to expanding access to…
December 2